Brown-Forman Corporation Class B vs Canopy Growth Corp — how do they compare? Brown-Forman Corporation Class B trades at $27.99, while Canopy Growth Corp trades at $1.03 (market cap $421.10M). The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| BF.B | CGC | |
|---|---|---|
Sector | Consumer Staples | Health |
52-Week High | $31.26 | $1.92 |
52-Week Low | $22.80 | $0.86 |
Market Cap | — | $421.10M |
Enterprise Value | — | $378.55M |
Signals from Pluang's Aura AI — not financial advice
Brown-Forman Class B (BF.B) trades at $28.03, down 0.57% on the day. The stock shows a bullish technical trend with moving averages supporting upside, while oscillators are neutral. Recent earnings have beaten expectations in three of the last four quarters, with Q2 2024 EPS of $0.48 exceeding the $0.46 estimate. Analyst sentiment is mixed, with a 25% buy rating amid divided coverage.
The outlook is cautiously optimistic given earnings momentum, but risks include competitive pressures and market volatility. Investment appeal hinges on sustained profit growth, though the lack of clear valuation metrics and mixed analyst views suggest a balanced risk-reward profile for investors.
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
Trailing returns across standard periods
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →